The stock of Verona Pharma Plc ADR (NASDAQ: VRNA) has increased by 0.04 when compared to last closing price of 74.09.Despite this, the company has seen a gain of 6.60% in its stock price over the last five trading days. globenewswire.com reported 2025-05-21 that LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025:
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
Company’s 36-month beta value is 0.18.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 76.70M, and currently, short sellers hold a 10.43% ratio of that floaft. The average trading volume of VRNA on May 22, 2025 was 1.44M shares.
VRNA’s Market Performance
The stock of Verona Pharma Plc ADR (VRNA) has seen a 6.60% increase in the past week, with a 17.07% rise in the past month, and a 9.06% gain in the past quarter. The volatility ratio for the week is 4.38%, and the volatility levels for the past 30 days are at 5.23% for VRNA. The simple moving average for the last 20 days is 5.56% for VRNA’s stock, with a simple moving average of 56.83% for the last 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with TD Cowen repeating the rating for VRNA by listing it as a “Buy.” The predicted price for VRNA in the upcoming period, according to TD Cowen is $100 based on the research report published on April 28, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $80. The rating they have provided for VRNA stocks is “Overweight” according to the report published on April 21st, 2025.
ROTH MKM gave a rating of “Buy” to VRNA, setting the target price at $68 in the report published on January 10th of the current year.
VRNA Trading at 14.36% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.96% of loss for the given period.
Volatility was left at 5.23%, however, over the last 30 days, the volatility rate increased by 4.38%, as shares surge +15.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.56% upper at present.
During the last 5 trading sessions, VRNA rose by +7.49%, which changed the moving average for the period of 200-days by +270.73% in comparison to the 20-day moving average, which settled at $70.25. In addition, Verona Pharma Plc ADR saw 59.60% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from VIKAS SINHA, who proposed sale 20,000 shares at the price of $72.58 back on May 20 ’25. After this action, VIKAS SINHA now owns shares of Verona Pharma Plc ADR, valued at $1,451,600 using the latest closing price.
Fisher Andrew, the General Counsel of Verona Pharma Plc ADR, sale 80,000 shares at $8.57 during a trade that took place back on May 15 ’25, which means that Fisher Andrew is holding 359,999 shares at $685,600 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -1.16 for the present operating margin
- 0.95 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -1.38. The total capital return value is set at -0.29. Equity return is now at value -72.73, with -40.26 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -56.16. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11.7.
Currently, EBITDA for the company is -142.19 million with net debt to EBITDA at 2.27. When we switch over and look at the enterprise to sales, we see a ratio of 50.34. The receivables turnover for the company is 1.91for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.86.
Conclusion
In a nutshell, Verona Pharma Plc ADR (VRNA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
